Skip to main content
Fig. 6 | Cancer Cell International

Fig. 6

From: AGI-134: a fully synthetic α-Gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma models

Fig. 6

AGI-134 synergizes with an anti-PD-1 antibody. a Schematic for testing efficacy of AGI-134 in combination with RMP1-14, an anti-PD-1 antibody. b On Day 5 after B16-F10 cell grafting, mice were treated i.t. with single 100 or 250 µg doses of AGI-134 or vehicle, and then intraperitoneally with four 250-μg doses of RMP1-14 or vehicle in 3–4-day intervals starting on Day 8 (experiment #1) or Day 10 (experiment #2) post B16-F10 cell grafting. For the graph, the data from two independent experiments were combined and plotted. The data show the percentage of mice free from secondary tumors over time. The treatment groups were statistically compared by Mantel–Cox test (*p < 0.05; **p < 0.005; ***p < 0.0005). Solid arrows indicate the time of i.t. AGI-134 or vehicle treatment; dashed arrows show the start of i.p. RMP1-14 treatment

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us